Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure

Journal of General Internal Medicine

Volumn 12, Issue 9, 1997, Pages 523-530

  Chin, Marshall H ^a   Friedmann, Peter D ^a   Cassel, Christine K ^a,b   Lang, Roberto M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Angiotensin converting enzyme (ACE) inhibitor; Congestive heart failure; Physician behavior; Quality of care; Specialty

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; BEHAVIOR; CONGESTIVE HEART FAILURE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MEDICAL SPECIALIST; PATIENT CARE; PHYSICIAN ATTITUDE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOLOGY; CLINICAL COMPETENCE; DRUG UTILIZATION REVIEW; FAMILY PRACTICE; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEART FAILURE, CONGESTIVE; HUMANS; INTERNAL MEDICINE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES;

EID: 0030808580     PISSN: 08848734     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1497.1997.07105.x     Document Type: Article

References (33)

1. Franks P, Nutting PA, Clancy CM. Health care reform, primary care, and the need for research. JAMA. 1993;270:1449-53.
2. Kassirer JP. Access to specialty care. N Engl J Med. 1994;331: 1151-3.
3. Stevenson WG, Stevenson L, Middlekauff HR, et al. Improving survival for patients with advanced heart failure: a study of 737 consecutive patients. J Am Coll Cardiol. 1995;26:1417-23.
4. Garg R, Yusuf S. Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450-6.
5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-91.
7. Pfeffer MA, Braunwald E, Move LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
8. Konstam M, Dracup K, Baker D, et al. Heart Failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. Rockville, Md: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; June 1994. AHCPR publication no. 94-0612.
9. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol. 1995;26:1376-98.
10. Young JB, Weiner DH, Yusuf S, et al. Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J. 1995; 88:514-23.
11. Bourassa MG, Gurne O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. J Am Coll Cardiol. 1993;22(suppl A):14-9A.
12. McDermott MM, Feinglass J, Sy J, Gheorghiade M. Hospitalized congestive heart failure patients with preserved versus abnormal left ventricular systolic function: clinical characteristics and drug therapy. Am J Med. 1995;99:629-35.
13. Chin MH, Goldman L. Factors contributing to the hospitalization of patients with congestive heart failure. Am J Public Health. 1997;87:643-8.
14. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 1994;71:584-7.
15. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol. 1993; 22(suppl A):198-200A.
16. Chin MH, Wang JC, Zhang JX, Lang RM. Utilization and dosing of angiotensin-converting enzyme inhibitors for heart failure: effect of physician specialty and patient characteristics. J Gen Intern Med. 1997;12:563-6.
17. Aday LA. Designing and Conducting Health Surveys. San Francisco, Calif: Jossey-Bass Publishers; 1989:121-4.
18. Stross JK, Harlan WR. The dissemination of new medical information. JAMA. 1979;241:2622-4.
19. Packer M. Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? J Am Coll Cardiol. 1996;28:1323-7.
20. Massie BM, Kramer BL, Topic N. Lack of relationship between short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation. 1984;69:1135-41.
21. Swedberg K, Eneroth P, Kjekshus J, Snapinn S, and the CONSENSUS Trial Study Group. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS Trial). Am J Cardiol. 1990;66:40-5D.
22. Jones TV, Gerrity MS, Earp J. Written case simulations: do they predict physicians' behavior? J Clin Epidemiol. 1990;43:805-15.
23. Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-42.
24. Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med. 1996;124:414-21.
25. Hlatky MA, Fleg JL, Hinton PC, et al. Physician practice in the management of congestive heart failure. J Am Coll Cardiol. 1986; 8:966-70.
26. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q. 1989;67:268-317.
27. Leape LL. Practice guidelines and standards: an overview. Qual Rev Bull. 1990;16:42-9.
28. Hillman AL, Pauly MV, Kerman K, Martinek CR. HMO managers' views on financial incentives and quality. Health Affairs. 1991; 10:207-219.
29. Kerr EA, Mittman BS, Hays RD, Siu AL, Leake B, Brook RH. Managed care and capitation in California: how do physicians at financial risk control their own utilization? Ann Intern Med. 1995;123:500-4.
30. Greco PJ, Eisenberg JM. Changing physicians' practices. N Engl J Med. 1993;329:1271-3.
31. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med. 1995;333:1190-5.
32. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. Am J Cardiol. 1997;79:58-63.
33. Health Care Financing Review, Statistical Supplement. Baltimore. Md: U.S. Department of Health and Human Services; 1995:56.